Preliminary study of glyceryl phenylbutyrate therapy for Ornithine transcarbamylase deficiency and a literature review.
10.3760/cma.j.cn511374-20220624-00423
- Author:
Duo ZHOU
1
;
Xiaohong SHANG
;
Yu QIAO
;
Yi CHENG
;
Zinan YU
;
Xinwen HUANG
Author Information
1. Department of Genetics and Metabolism, the Children's Hospital Affiliated to Zhejiang University School of Medicine, National Clinical Research Center for Child Health, National Children's Regional Medical Center, Hangzhou, Zhejiang 310052, China. 6305022@zju.edu.cn.
- Publication Type:Journal Article
- MeSH:
Child;
Humans;
Ornithine Carbamoyltransferase Deficiency Disease/drug therapy*;
Phenylbutyrates/therapeutic use*;
Ammonia;
Retrospective Studies
- From:
Chinese Journal of Medical Genetics
2023;40(9):1107-1112
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the efficacy and safety of glyceryl phenylbutyrate (GPB) therapy for patients with Ornithine transcarbamylase deficiency (OTCD).
METHODS:Two children with OTCD were selected as the study subjects, and their clinical manifestations, blood ammonia, liver enzymes, growth and development information following the treatment with GPB were retrospectively analyzed. A literature review was also carried out by searching the PubMed database for studies on the GPB treatment for urea cycle disorders.
RESULTS:With the GPB treatment, the blood ammonia and liver enzyme level in both patients have decreased to the normal range within 3 months. Motor development in child 2 has improved. No adverse reaction was noted, except for transient palmar greasy smell and loss of appetite in child 1. Analysis of the literature showed that patients had lower ammonia exposure, lower annual incidence of hyperammonemic crisis, more actual protein intake and fewer adverse events during GPB treatment.
CONCLUSION:GPB is safe and effective for the treatment of OTCD.
